Loxo Oncology, Stock Today

Loxo Oncology, cannot be verified against its exchange. Apparently, Loxo Oncology, is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Loxo Oncology, Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Loxo Oncology,'s investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Loxo Oncology, or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Loxo Oncology, is not currently marked as verified by its exchange. Report It!
Loxo Oncology, Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Loxo Oncology, SEC Filings
Loxo Oncology, SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameLoxo Oncology,
President CEO, DirectorJoshua Bilenker  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Cancer Fighters
Average Analyst Recommendation
Analysts covering Loxo Oncology, report their recommendations after researching Loxo Oncology,'s financial statements, talking to executives and customers, or listening in on Loxo Oncology,'s conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Loxo Oncology,. The Loxo Oncology, consensus assessment is calculated by taking the average forecast from all of the analysts covering Loxo Oncology,.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Loxo Oncology, based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Loxo Oncology, financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares27.2 M25.2 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted27.2 M25.2 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations104.6 M97 M
Significantly Up
Increasing
Slightly volatile
Total Assets760.8 M705.1 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities393.5 M364.7 M
Significantly Up
Increasing
Slightly volatile
Current Assets759.2 M703.6 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities215.2 M199.4 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Loxo Oncology,'s available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
Loxo Oncology, (LOXO) is traded on NASDAQ Exchange in USA. It is located in 281 Tresser Blvd, 9th Floor, Stamford, CT 06901, United States and employs 59 people. Loxo Oncology, is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 7.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Loxo Oncology,'s market, we take the total number of its shares issued and multiply it by Loxo Oncology,'s current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Loxo Oncology, conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 30.75 M outstanding shares of which 1.03 M shares are now shorted by private and institutional investors with about 0.5 trading days to cover. Loxo Oncology, currently holds about 622 M in cash with 234.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71.
Check Loxo Oncology, Probability Of Bankruptcy

Loxo Oncology, Stock Against Markets

Picking the right benchmark for Loxo Oncology, stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Loxo Oncology, stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Loxo Oncology, is critical whether you are bullish or bearish towards Loxo Oncology, at a given time.
Loxo Oncology, cannot be verified against its exchange. Apparently, Loxo Oncology, is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Loxo Oncology, stock to make a market-neutral strategy. Peer analysis of Loxo Oncology, could also be used in its relative valuation, which is a method of valuing Loxo Oncology, by comparing valuation metrics with similar companies.

Loxo Oncology, Corporate Directors

Loxo Oncology, corporate directors refer to members of a Loxo Oncology, board of directors. The board of directors generally takes responsibility for the Loxo Oncology,'s affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Loxo Oncology,'s board members must vote for the resolution. The Loxo Oncology, board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
James Barrett - Independent DirectorProfile
Timothy Mayleben - Independent DirectorProfile
Avraham Naider - Independent DirectorProfile
Lori Kunkel - DirectorProfile
Check out Stocks Correlation. Note that the Loxo Oncology, information on this page should be used as a complementary analysis to other Loxo Oncology,'s statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Tools for Loxo Oncology, Stock

When running Loxo Oncology, price analysis, check to measure Loxo Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Loxo Oncology, is operating at the current time. Most of Loxo Oncology,'s value examination focuses on studying past and present price action to predict the probability of Loxo Oncology,'s future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Loxo Oncology,'s price. Additionally, you may evaluate how the addition of Loxo Oncology, to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go